Last reviewed · How we verify
cannabidiol and tetrahydrocannabinol
At a glance
| Generic name | cannabidiol and tetrahydrocannabinol |
|---|---|
| Also known as | CBD/THC, CBD and THC |
| Sponsor | FG Brasil LTDA |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Exploring The Effect Of Cannabidiol On Cannabis Tolerance Using A Novel Vaporiser Device In Heavy Users (Stage 1) (NA)
- Unique Treatment of Oncology Pain in Advanced Cancer (PHASE2)
- Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden (PHASE2)
- Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (PHASE3)
- Wayne State Warriors Marijuana Clinical Research Program: Cannabinoid Adjunct to Prolonged Exposure & Recovery (PHASE1)
- Cannabidiol Into Breastmilk (NA)
- Safety and Efficacy of Oral Cannabis in Chronic Spine Pain (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cannabidiol and tetrahydrocannabinol CI brief — competitive landscape report
- cannabidiol and tetrahydrocannabinol updates RSS · CI watch RSS
- FG Brasil LTDA portfolio CI